Nattokinase (serine protease from fermented soybean natto, Bacillus subtilis var. natto)

Nattokinase is presented as «healthy-vessel and longevity protection» on TikTok, at anti-ageing conferences, and in preventive-medicine clinics. The hypothesis leans on Japan's low cardiovascular disease rate and traditional natto breakfast consumption. This correlation has been examined repeatedly in epidemiology, but population-level causality between natto and cardiologic longevity has not been established – lower BMI, fish and tea intake, low red-meat consumption, low obesity prevalence, and active lifestyle drive most of the signal. The correlation does not transfer to capsules of purified nattokinase: RCTs with hard endpoints of lifespan or cardiovascular mortality have not been done. Chen 2018 (Biomark Insights) reviewed small series showing 3–5 mm Hg systolic blood-pressure reductions in short-term studies, but methodological quality is low (open-label, small samples, varied doses). AHA and ESC prevention guidelines rely on blood-pressure control (target 120–129 mm Hg for most), statins for dyslipidaemia, metformin and incretins for diabetes, smoking cessation, and a Mediterranean diet. Nattokinase is not in these recommendations.

Nattokinase is actively marketed as a «natural blood thinner» for stroke and clot prevention, especially after long-haul flights, in varicose veins, or atrial fibrillation. The evidence for this use is absent. RCTs of nattokinase with hard endpoints (pulmonary embolism, deep-vein thrombosis, ischaemic stroke, cardioembolism) in humans have not been performed. ESC Guidelines 2024 for atrial fibrillation and AHA stroke prevention recommend vitamin K antagonists (warfarin, acenocoumarol) or DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) with selection by CHA2DS2-VASc and HAS-BLED scores; mechanical heart valves require warfarin. Approved anticoagulants have measurable effects (INR, anti-Xa) and reduce stroke incidence by 60–70%. Switching from an anticoagulant to nattokinase in atrial fibrillation or after pulmonary embolism is dangerous: the effect is unpredictable, doses are not standardised, and the enzyme does not appear in any current cardiology guideline. FDA in 2022 issued warning letters to nattokinase supplement makers for illegal myocardial-infarction and stroke prevention claims. If nattokinase was prescribed instead of apixaban or warfarin, consider seeking a second opinion with a cardiologist – swapping proven anticoagulation for a supplement carries a real stroke risk.

ICD-10: I82 · ICD-11: BD71

Nattokinase is often pitched as a «natural blood detox», «vessel cleanser», and a way to «remove fibrin deposits» – especially in anti-ageing and biohacking concepts. The «vessel cleansing by a plant enzyme» idea is physiologically untenable: atherosclerotic plaque is not made of fibrin (which nattokinase might split), but of cholesterol deposits, a fibrous cap, calcium, immune cells, and vascular matrix. These structures are not dissolved by an oral enzyme. Modern atherosclerosis prevention runs on statins, ezetimibe, PCSK9 inhibitors when indicated, and blood-pressure and glucose control. EFSA has not authorised any nattokinase health claim under EC 1924/2006; AESAN through RD 1487/2009 prohibits supplement manufacturers from claiming disease prevention or treatment. FDA issued warning letters to nattokinase manufacturers in 2022 for illegal myocardial-infarction and stroke prevention claims.